Format

Send to:

Choose Destination
See comment in PubMed Commons below
Schizophr Res. 2004 Nov 1;71(1):97-101.

Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder.

Author information

  • 1University of Pittsburgh Medical Center, Health System-Western Psychiatric Institute and Clinic, Room 984, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. keshavanms@msx.upmc.edu

Abstract

BACKGROUND:

Few treatment studies of schizotypal personality disorder (SPD) have investigated the new, atypical antipsychotic drugs. This study examined the efficacy and tolerability of olanzapine, an atypical antipsychotic drug, in a series of patients with DSM-IV diagnosed schizotypal personality disorder.

METHOD:

This was a 26-week, open-label study with flexible dose design in 11 subjects with a diagnosis of schizotypal personality disorder based on Structured Clinical Interview for DSM-IV (SCID) and Personality Disorder Examination (PDE Journal of Psychiatric Disorders 1 (1987) 1). Subjects were treated with a low dose (average 9.32 mg/day) of olanzapine. Psychopathology was assessed at baseline and at the end of the study and analyzed with last observation carried forward analysis.

RESULTS:

Patients showed significant improvements in psychosis and depression ratings, as well as in overall functioning. Olanzapine was well tolerated, though significant weight gain was observed.

CONCLUSION:

This study provides preliminary data regarding olanzapine efficacy and tolerability in schizotypal personality disorder subjects. These data need to be confirmed in larger controlled clinical trials.

PMID:
15374577
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk